JonathanMarkDucoreMD

Pediatric Hematology & Oncology • Sacramento, CA

Emeritus Professor of Clinical Pediatrics Director Hemostasis and Thrombosis Center

Join to view full profile

Dr. Ducore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ducore's full profile

Already have an account?

Office
2000 Stockton Blvd
TICON I Bldg
Sacramento, CA 95817
Phone+1 916-734-3461

Fax+1 916-734-3591

Education & Training

University of ColoradoResidency, Pediatrics, 1975 - 1977
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1974 - 1975
University of Cincinnati Medical Center Inc.Internship, Transitional Year, 1973 - 1974
Duke University School of MedicineClass of 1973

Certifications & Licensure

CA State Medical License 1988 - 2025
TX State Medical License 1980 - 2018
MD State Medical License 1978 - 1990
CO State Medical License 1975 - 1989
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Publications & Presentations

PubMed

1 citations
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
Mark T Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore
Drugs in R&D. 2024-09-01
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.
Mark T Reding, Mindy Simpson, Jonathan Ducore, Pål Andrè Holme, Monika Maas Enriquez
Acta Haematologica. 2024-04-23
1 citations
Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
Mary Mathias, Aby Abraham, Mark J Belletrutti, Manuel Carcao, Manuela Carvalho
European Journal of Haematology. 2023-10-01

Abstracts/Posters

Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year
Jonathan M. Ducore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

UC Davis Health Discovers Increased Risk of Leukemia in Children with down SyndromeMay 7th, 2021
Miracle of Hemophilia Drugs Comes at A Steep PriceMarch 5th, 2018
Octapharma Announces Two Hemophilia A Clinical Trials to Utilize WILATENovember 14th, 2016

Grant Support

RNA Changes By L-PAM In Human CellsNational Cancer Institute1988–1989
RNA Changes By L-PAM In Human CellsNational Cancer Institute1986–1988
Mechanism Of Action Of Bifunctional Alkylating AgentsNational Cancer Institute1985